ATLANTA--(BUSINESS WIRE)--AMNIOX Medical, Inc., a TissueTech, Inc. company has announced an agreement with Intalere, to serve their members with its market leading human tissue allograft technology composed of both umbilical cord and amniotic membrane for wound healing and soft-tissue repair. Intalere is a professional supply chain company offering a comprehensive suite of services to empower healthcare providers to better manage their entire spend and ultimately deliver superior care.
The agreement includes NEOX® and CLARIX® CORD 1K®, 100 and FLO, and NEOX CORD RT in the Intalere advanced wound care-bioactive category. Preferred pricing for Intalere members extends to 3,651 acute care hospitals, 174 hospital-based physicians and 3,680 ambulatory surgery centers.
“This is a welcome partnership with an organization that prides itself on its ability to empower providers to serve their communities well, and serve them in a sustainable manner with the best medicine,” said Amniox Medical CEO Tom Dugan. “Intalere’s membership includes more than 65% of US hospitals and numerous ambulatory surgery centers, clinics and physician offices. In addition to expanding our presence around the country, this partnership highlights Amniox’s expanding leadership in providing regenerative medicine products that meet clinical needs effectively and deliver value.”
Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. The biological components of these tissues have demonstrated regenerative properties that can provide healing benefits to patients with numerous medical conditions. In utero, wound healing occurs rapidly and with minimal scar, and this restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Amniox utilizes its proprietary CryoTek® process, a cryopreservation technology, to preserve the biological and structural integrity of the native tissue which published studies have demonstrated preserves the HC-HA/PTX3 matrix that is key to the regenerative process.
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue focuses on products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. Visit http://tissuetech.com to learn more.
Intalere’s mission focuses on elevating the operational health of America’s healthcare providers by designing tailored, smart solutions that deliver optimal cost, quality and clinical outcomes. We strive to be the essential partner for operational excellence in healthcare through customized solutions that address customers’ individual needs. We assist our customers in managing their entire spend, providing innovative technologies, products and services, and leveraging the best practices of a provider-led model. As Intalere draws on the power of our owner Intermountain Healthcare’s nationally-recognized supply chain expertise and leadership in technology, process improvement, and evidence-based clinical and business best practices, we are uniquely positioned to be the innovation leader in the healthcare industry. Visit http://www.intalere.com to learn more.